Okay, let's tackle this question about FTA-ABS in syphilis. The question is asking which statement is NOT true about the FTA-ABS test. First, I need to recall what FTA-ABS stands for. FTA-ABS is the Fluorescent Treponemal Antibody Absorption test. It's a specific test for syphilis that detects antibodies against the Treponema pallidum bacterium.

The core concept here is understanding the characteristics of FTA-ABS. It's a treponemal test, which means it's used to confirm syphilis after a non-treponemal test like RPR or VDRL is positive. Key points about FTA-ABS include that it's highly specific, not affected by recent treatment, and remains positive for life once infected. Also, it doesn't cross-react with other spirochetal infections like Lyme disease, which is important.

Now, the question is about the exception. Let's think about the options. If an option says FTA-ABS becomes negative after successful treatment, that's incorrect because FTA-ABS remains positive. Another incorrect option might be that it's a non-treponemal test, which is wrong because it's a treponemal test. Also, if an option claims it's used for initial screening, that's wrong since it's a confirmatory test. Another possible wrong answer is that it can be used in CSF, which isn't true because FTA-ABS isn't used for CSF; for neurosyphilis, tests like VDRL-CSF or FTA-ABS for CSF (though less common) are used. Wait, actually, there's a version called FTA-ABS for CSF, but maybe the options are suggesting it's used in CSF without specifying. Need to check that.

So, the correct answer would be the one that states FTA-ABS becomes negative after treatment. That's the exception. The other options would be correct statements about FTA-ABS. The clinical pearl here is that FTA-ABS is a confirmatory test with lifelong positivity, and it's not used for monitoring treatment response, which is done with non-treponemal tests like RPR or VDRL. Also, remember that it's specific for T. pallidum and doesn't cross-react with other spirochetes.

**Core Concept**
The Fluorescent Treponemal Antibody Absorption (FTA-ABS) test is a **treponemal-specific** serological assay for syphilis. It detects antibodies against *Treponema pallidum* and is used for **confirmatory diagnosis** after non-treponemal tests like RPR/VDRL. It remains **positive for life** regardless of treatment, distinguishing it from non-treponemal tests.

**Why the Correct Answer is Right**
FTA-ABS is **highly specific** (95–98%) and does **not cross-react** with antibodies from other spirochetal infections (e.g., Lyme disease). It is **not affected by penicillin treatment** and remains positive indefinitely. The exception in the question is likely the claim that FTA-ABS **loses positivity after treatment**, which is false because it detects IgG antibodies that persist permanently.

**Why Each Wrong Option is Incorrect

✓ Correct Answer: A. FTA - ABS becomes negative after treatment